1. Home
  2. ACOG vs CELU Comparison

ACOG vs CELU Comparison

Compare ACOG & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACOG
  • CELU
  • Stock Information
  • Founded
  • ACOG 2000
  • CELU 2016
  • Country
  • ACOG Canada
  • CELU United States
  • Employees
  • ACOG N/A
  • CELU N/A
  • Industry
  • ACOG
  • CELU Biotechnology: Pharmaceutical Preparations
  • Sector
  • ACOG
  • CELU Health Care
  • Exchange
  • ACOG Nasdaq
  • CELU Nasdaq
  • Market Cap
  • ACOG 80.3M
  • CELU 64.3M
  • IPO Year
  • ACOG N/A
  • CELU N/A
  • Fundamental
  • Price
  • ACOG $8.58
  • CELU $2.19
  • Analyst Decision
  • ACOG Strong Buy
  • CELU Strong Buy
  • Analyst Count
  • ACOG 1
  • CELU 1
  • Target Price
  • ACOG $20.00
  • CELU $6.00
  • AVG Volume (30 Days)
  • ACOG 65.4K
  • CELU 147.3K
  • Earning Date
  • ACOG 11-14-2025
  • CELU 08-29-2025
  • Dividend Yield
  • ACOG N/A
  • CELU N/A
  • EPS Growth
  • ACOG N/A
  • CELU N/A
  • EPS
  • ACOG N/A
  • CELU N/A
  • Revenue
  • ACOG $4,586,341.00
  • CELU $44,590,000.00
  • Revenue This Year
  • ACOG N/A
  • CELU N/A
  • Revenue Next Year
  • ACOG $149.89
  • CELU $76.00
  • P/E Ratio
  • ACOG N/A
  • CELU N/A
  • Revenue Growth
  • ACOG N/A
  • CELU 4.45
  • 52 Week Low
  • ACOG $3.75
  • CELU $1.00
  • 52 Week High
  • ACOG $11.54
  • CELU $5.22
  • Technical
  • Relative Strength Index (RSI)
  • ACOG 45.31
  • CELU 35.90
  • Support Level
  • ACOG $8.15
  • CELU $2.05
  • Resistance Level
  • ACOG $10.00
  • CELU $2.41
  • Average True Range (ATR)
  • ACOG 0.56
  • CELU 0.29
  • MACD
  • ACOG 0.01
  • CELU -0.08
  • Stochastic Oscillator
  • ACOG 30.63
  • CELU 8.59

About ACOG Alpha Cognition Inc. Common Stock

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: